Orris

FIBRO scan

Reading File
Finding Sources
Finding Sources
Searching Images

FibroScan transient elastography liver fibrosis assessment

A diagnostic graphical output from a transient elastography (FibroScan) assessment used to evaluate liver stiffness and steatosis. The image features two horizontal bar graphs. The top bar represents the 'Fibro score' (liver stiffness in kilopascals, kPa), showing a color-coded gradient corresponding to Metavir fibrosis stages: dark green (F0), light green (F0F1), yellow (F2), orange (F2F3), and red (F4/cirrhosis). A specific value of 35.3 kPa is highlighted, indicating advanced cirrhosis. The lower bar represents the 'Controlled Attenuation Parameter (CAP) score' (measured in dB/m) used to quantify hepatic steatosis. This bar shows a green segment reaching a value of 211 dB/m on a scale up to 400.0, suggesting a low level of fat accumulation (S0). The graphic is a standard clinical tool in gastroenterology and hepatology for non-invasive monitoring of chronic liver disease, providing a visual comparison between fibrosis severity and steatosis levels.

A diagnostic graphical output from a transient elastography (FibroScan) assessment used to evaluate liver stiffness and steatosis. The image features two horizontal bar graphs. The top bar represents the 'Fibro score' (liver stiffness in kilopascals, kPa), showing a color-coded gradient corresponding to Metavir fibrosis stages: dark green (F0), light green (F0F1), yellow (F2), orange (F2F3), and red (F4/cirrhosis). A specific value of 35.3 kPa is highlighted, indicating advanced cirrhosis. The lower bar represents the 'Controlled Attenuation Parameter (CAP) score' (measured in dB/m) used to quantify hepatic steatosis. This bar shows a green segment reaching a value of 211 dB/m on a scale up to 400.0, suggesting a low level of fat accumulation (S0). The graphic is a standard clinical tool in gastroenterology and hepatology for non-invasive monitoring of chronic liver disease, providing a visual comparison between fibrosis severity and steatosis levels.

This composite diagnostic image demonstrates a comparative assessment of liver fibrosis in a 48-year-old female with chronic hepatitis B using two elastography modalities. Image A shows a 2D Shear Wave Elastography (SWE) examination. The top pane displays a B-mode ultrasound of the liver with a color-coded shear wave velocity map (ranging from 0.0 to 4.0+ m/s) overlaid on a region of interest. Numerical data indicates velocities (V10: 7.05 m/s, V11: 2.99 m/s, V12: 2.49 m/s) at a depth of 7.24 cm, which was interpreted as significant fibrosis (Metavir F2). Image B displays a Transient Elastography (FibroScan) report. The left side shows the B-mode ultrasound guide, while the right side presents quantitative data: a Controlled Attenuation Parameter (CAP) of 312 dB/m (indicating steatosis) and a liver stiffness measurement (E) of 2.9 kPa with an IQR/median of 4%. These FibroScan findings are consistent with no significant fibrosis (Metavir F0), illustrating a clinical discrepancy between SWE and TE results in the same patient. The visual serves to educate on non-invasive liver stiffness measurement techniques and the potential for overestimation in specific modalities.

This composite diagnostic image demonstrates a comparative assessment of liver fibrosis in a 48-year-old female with chronic hepatitis B using two elastography modalities. Image A shows a 2D Shear Wave Elastography (SWE) examination. The top pane displays a B-mode ultrasound of the liver with a color-coded shear wave velocity map (ranging from 0.0 to 4.0+ m/s) overlaid on a region of interest. Numerical data indicates velocities (V10: 7.05 m/s, V11: 2.99 m/s, V12: 2.49 m/s) at a depth of 7.24 cm, which was interpreted as significant fibrosis (Metavir F2). Image B displays a Transient Elastography (FibroScan) report. The left side shows the B-mode ultrasound guide, while the right side presents quantitative data: a Controlled Attenuation Parameter (CAP) of 312 dB/m (indicating steatosis) and a liver stiffness measurement (E) of 2.9 kPa with an IQR/median of 4%. These FibroScan findings are consistent with no significant fibrosis (Metavir F0), illustrating a clinical discrepancy between SWE and TE results in the same patient. The visual serves to educate on non-invasive liver stiffness measurement techniques and the potential for overestimation in specific modalities.

This composite diagnostic image demonstrates non-invasive liver fibrosis assessment in a 52-year-old male with chronic hepatitis C. Panel A displays a 2D Shear Wave Elastography (SWE) ultrasound of the liver. It features a B-mode grayscale image with a colored elasticity map overlay. A color-coded scale (0.0 to 4.0 m/s) indicates tissue stiffness, where red signifies higher shear wave velocity. Measurement data shows velocity values ranging from 2.66 to 3.13 m/s (median 2.62 m/s), corresponding to a Metavir F4 (cirrhosis) stage. Panel B shows a FibroScan (Transient Elastography) interface. Quantitative findings include a Controlled Attenuation Parameter (CAP) of 294 dB/m (indicating hepatic steatosis) and a liver stiffness measurement (E) of 64.0 kPa with an IQR/median ratio of 16%. The FibroScan display includes individual measurement graphs showing shear wave propagation. Both modalities consistently indicate advanced fibrosis/cirrhosis (F4). This content is representative of hepatology and radiology diagnostic protocols for monitoring chronic liver disease progression.

This composite diagnostic image demonstrates non-invasive liver fibrosis assessment in a 52-year-old male with chronic hepatitis C. Panel A displays a 2D Shear Wave Elastography (SWE) ultrasound of the liver. It features a B-mode grayscale image with a colored elasticity map overlay. A color-coded scale (0.0 to 4.0 m/s) indicates tissue stiffness, where red signifies higher shear wave velocity. Measurement data shows velocity values ranging from 2.66 to 3.13 m/s (median 2.62 m/s), corresponding to a Metavir F4 (cirrhosis) stage. Panel B shows a FibroScan (Transient Elastography) interface. Quantitative findings include a Controlled Attenuation Parameter (CAP) of 294 dB/m (indicating hepatic steatosis) and a liver stiffness measurement (E) of 64.0 kPa with an IQR/median ratio of 16%. The FibroScan display includes individual measurement graphs showing shear wave propagation. Both modalities consistently indicate advanced fibrosis/cirrhosis (F4). This content is representative of hepatology and radiology diagnostic protocols for monitoring chronic liver disease progression.

This diagnostic image displays a portion of a Fibroscan result, a non-invasive imaging modality used to assess liver stiffness and steatosis. The image features a horizontal band containing color-coded data, transitioning from a green hue with vertical striations on the far left to a dominant, solid blue field across the center and right. Additional faint vertical patterns appear on the far right. Centered within this blue band are two white text labels: 'None alcohol Fatty Liver Disease' (top) and 'Hepatitis B' (bottom). The visual demonstrates clinical findings in the context of liver disease assessment, specifically comparing the effects of different etiologies or concurrent conditions such as hepatic hemangioma on transient elastography measurements. The educational focus is on identifying visual patterns related to liver stiffness (measured in kilopascals) and controlled attenuation parameter (CAP) scores, which are critical for staging fibrosis and steatosis in chronic liver diseases.

This diagnostic image displays a portion of a Fibroscan result, a non-invasive imaging modality used to assess liver stiffness and steatosis. The image features a horizontal band containing color-coded data, transitioning from a green hue with vertical striations on the far left to a dominant, solid blue field across the center and right. Additional faint vertical patterns appear on the far right. Centered within this blue band are two white text labels: 'None alcohol Fatty Liver Disease' (top) and 'Hepatitis B' (bottom). The visual demonstrates clinical findings in the context of liver disease assessment, specifically comparing the effects of different etiologies or concurrent conditions such as hepatic hemangioma on transient elastography measurements. The educational focus is on identifying visual patterns related to liver stiffness (measured in kilopascals) and controlled attenuation parameter (CAP) scores, which are critical for staging fibrosis and steatosis in chronic liver diseases.

Reading File
Reading File
Reading File
Searching PubMed

FibroScan transient elastography liver fibrosis

I now have excellent textbook content, images, and recent literature. Let me compile the full answer.

FibroScan (Vibration-Controlled Transient Elastography - VCTE)

What Is It?

FibroScan is a non-invasive bedside device that measures hepatic (liver) stiffness using low-frequency elastic shear waves. It is marketed by Echosens and was approved by the FDA in 2013 for use in patients with liver disease. The underlying principle is that fibrosis increases the stiffness of liver tissue, and a shear wave propagates faster through stiffer material than through elastic material.

How It Works

The US transducer emits a low-frequency (50 Hz) shear wave into the liver, and the time required for the wave to pass through a defined tissue window is measured.
  • The measurement window is 1 cm × 4 cm - approximately 100 times the area of a standard liver biopsy specimen, greatly reducing sampling error.
  • Results are expressed in kilopascals (kPa).
  • Modern FibroScan also measures the Controlled Attenuation Parameter (CAP) in dB/m, which quantifies hepatic steatosis (fat content).
  • Sleisenger & Fordtran's GI and Liver Disease

Two Key Outputs

ParameterWhat It MeasuresUnitClinical Use
Liver Stiffness (E)Degree of hepatic fibrosiskPaStaging fibrosis (F0-F4/METAVIR)
CAP ScoreHepatic fat (steatosis)dB/mGrading steatosis (S0-S3)

Fibrosis Staging: METAVIR Scale

FibroScan results are reported using the METAVIR system:
METAVIR StageMeaningApproximate kPa Threshold (Hep C)
F0No fibrosis< 7.0 kPa
F1Portal fibrosis, no septa< 7.0 kPa
F2Few septa~7.1 - 9.5 kPa
F3Numerous septa, no cirrhosis~9.5 - 12.5 kPa
F4Cirrhosis> 12.5 kPa
A meta-analysis found the area under the ROC curve (AUROC) for predicting cirrhosis = 0.94, indicating excellent diagnostic accuracy for cirrhosis. It performs best for differentiating cirrhosis from no cirrhosis but is less precise for intermediate stages.

FibroScan Output - Sample Images

Here is what a typical FibroScan result looks like:
FibroScan result showing Fibro score 35.3 kPa (F4 cirrhosis) and CAP score 211 dB/m (S0 steatosis)
The top bar shows fibrosis severity (color-coded F0 to F4); the bottom bar shows CAP score for steatosis. This example shows 35.3 kPa (advanced cirrhosis, F4) with low steatosis (211 dB/m, S0).
FibroScan vs 2D Shear Wave Elastography comparison in chronic hepatitis B patient
Comparison of FibroScan (Panel B, showing 2.9 kPa = F0) vs. 2D-SWE (Panel A, showing velocities consistent with F2). Illustrates how modalities can sometimes disagree.

Clinical Indications

FibroScan is used to assess liver fibrosis in:
  • Chronic Hepatitis B and Hepatitis C
  • NAFLD/NASH (non-alcoholic fatty liver disease)
  • Alcohol-associated liver disease
  • Primary biliary cholangitis (PBC)
  • Hemochromatosis
  • Post-liver transplant recurrent hepatitis
  • Monitoring hepatotoxicity in patients on methotrexate (e.g., for psoriasis, rheumatoid arthritis)

Advantages Over Liver Biopsy

FeatureLiver BiopsyFibroScan
InvasivenessInvasive, risk of bleedingCompletely non-invasive
Sample volumeSmall (1/50,000 of liver)100× larger "window"
Sampling errorUp to 33% 1-stage differenceNegligible
CostHighLower
RepeatabilityLimitedEasily repeatable
Steatosis assessmentYes (histology)Yes (CAP score)
Combining transient elastography with serum biomarkers (e.g., FibroTest/FibroSure) increases accuracy further and may avoid liver biopsy in many patients.

Limitations

  1. Obesity (BMI ≥ 30-40) - increased body habitus reduces reliability; an XL probe is available but still less accurate.
  2. Ascites - fluid impairs shear wave propagation.
  3. Hepatic inflammation - active necroinflammation can overestimate stiffness, independent of fibrosis stage.
  4. Poor at intermediate fibrosis - most accurate for F0-F1 vs. F4 extremes; less precise for F2-F3.
  5. Operator skill - requires adequate training; 10 valid measurements with an IQR/median ratio < 30% needed for reliability.
  6. Does not assess degree of hepatic inflammation (unlike biopsy).

Compared to Other Elastography Methods

MethodHow It WorksAdvantageLimitation
FibroScan (VCTE)50 Hz shear wave, 1DFast, cheap, validatedBMI, ascites limitations
2D-SWEShear wave with 2D imagingReal-time, better in obeseMore expensive
MR Elastography (MRE)65 Hz waves, MRI-basedWorks in obese/ascites, most accurateVery expensive, less accessible
One study showed MRE was superior to FibroScan for staging fibrosis across various chronic liver diseases, but at significantly higher cost. - Sleisenger & Fordtran's

Recent Evidence (2025)

A 2025 Lancet Gastroenterology & Hepatology systematic review and meta-analysis specifically assessed non-invasive tests including FibroScan for staging fibrosis/cirrhosis in chronic hepatitis B to inform the WHO 2024 guidelines (PMID: 39983746). A 2025 systematic review - "FibroScan's evolution: a critical 20-year review" - confirms its continued central role in hepatology practice (PMID: 39562432).

Summary

FibroScan is the most widely used non-invasive tool for liver fibrosis assessment. It measures liver stiffness in kPa (mapped to METAVIR stages F0-F4) and steatosis via CAP score. Its AUROC for cirrhosis detection is ~0.94. Its main limitations are reduced accuracy in obesity, ascites, and active hepatic inflammation. It cannot replace biopsy in all cases but has dramatically reduced the need for it in routine chronic liver disease monitoring.
This is a shared conversation. Sign in to Orris to start your own chat.